The Pennant Group, Inc. (PNTG) Insider Trading

Last 12 months

Insiders sold $690k and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in May 2023.

Net open-market

−$690k

0 buys · 6 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

May 2023

May 11, 2023

Get an email when PNTG's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 6	Jason Paul Steik Chief Clinical Officer	Sold10b5-1 plan	1,394	$38.52	$54k	8.4%	Form 4
Aug 6	Brent Guerisoli Chief Executive Officer	Sold10b5-1 plan	4,285	$38.52	$165k	4.1%	Form 4
Aug 6	Kirk Sterling Cheney EVP, GC and Corp Secy	Sold10b5-1 plan	1,393	$38.52	$54k	7.0%	Form 4
Jul 10	Brent Guerisoli Chief Executive Officer	Sold10b5-1 plan	3,159	$41.57	$131k	3.0%	Form 4
Jul 7	Brent Guerisoli Chief Executive Officer	Sold10b5-1 plan	3,165	$40.51	$128k	3.0%	Form 4
May 22	Brent Guerisoli Chief Executive Officer	Sold10b5-1 plan 4 parts	4,508	$35.08 average	$158k	4.4%	Form 4
Jul 28, 2025	Kirk Sterling Cheney EVP, GC and Corp Secy	Sold10b5-1 plan	880	$23.34	$21k	6.3%	Form 4
Jul 28, 2025	Brent Guerisoli Chief Executive Officer	Sold10b5-1 plan	3,995	$23.34	$93k	4.6%	Form 4
May 20, 2025	Joanne Stringfield Director	SoldNo plan	5,000	$29.47	$147k	14%	Form 4
May 1, 2025	Joanne Stringfield Director	Sold10b5-1 plan	665	$25.62	$17k	2.1%	Form 4
Jan 30, 2025	Joanne Stringfield Director	Sold10b5-1 plan	665	$27.88	$19k	2.2%	Form 4
Oct 23, 2024	Joanne Stringfield Director	Sold10b5-1 plan	380	$33.56	$13k	1.3%	Form 4

Aug 610b5-1 plan
Jason Paul Steik
Chief Clinical Officer · sold 1,394 at $38.52
$54k
8.4% of stake
Aug 610b5-1 plan
Brent Guerisoli
Chief Executive Officer · sold 4,285 at $38.52
$165k
4.1% of stake
Aug 610b5-1 plan
Kirk Sterling Cheney
EVP, GC and Corp Secy · sold 1,393 at $38.52
$54k
7.0% of stake
Jul 1010b5-1 plan
Brent Guerisoli
Chief Executive Officer · sold 3,159 at $41.57
$131k
3.0% of stake
Jul 710b5-1 plan
Brent Guerisoli
Chief Executive Officer · sold 3,165 at $40.51
$128k
3.0% of stake
May 2210b5-1 plan
Brent Guerisoli
Chief Executive Officer · sold 4,508 at avg $35.08
$158k
4.4% of stake
Jul 28, 202510b5-1 plan
Kirk Sterling Cheney
EVP, GC and Corp Secy · sold 880 at $23.34
$21k
6.3% of stake
Jul 28, 202510b5-1 plan
Brent Guerisoli
Chief Executive Officer · sold 3,995 at $23.34
$93k
4.6% of stake
May 20, 2025No plan
Joanne Stringfield
Director · sold 5,000 at $29.47
$147k
14% of stake
May 1, 202510b5-1 plan
Joanne Stringfield
Director · sold 665 at $25.62
$17k
2.1% of stake
Jan 30, 202510b5-1 plan
Joanne Stringfield
Director · sold 665 at $27.88
$19k
2.2% of stake
Oct 23, 202410b5-1 plan
Joanne Stringfield
Director · sold 380 at $33.56
$13k
1.3% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PNTG, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Health Services

INNVInnovAge Holding Corp.

USPHU.S. Physical Therapy Inc.

PIIIP3 Health Partners Inc.

LFSTLifeStance Health Group, Inc.

WGSGeneDx Holdings Corp.

OMDAOmada Health, Inc.

DCGODocGo Inc.

SRTAStrata Critical Medical, Inc.

Spot a number that looks wrong? Check it in PNTG's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PNTG

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.